Atenolol, a cardioselective beta-blocking agent, at dose levels of 003, 0-06, and 012 mg/kg intravenously, produced prolongation of atrioventricular nodal conduction in 22 patients with suspected coronary artery disease.
produced prolongation of atrioventricular nodal conduction in 22 patients with suspected coronary artery disease.
In a dose of 0O12 mg/kg body weight atenolol produced significant prolongation of sinus cycle length, sinus node recovery time, atrioventricular node conduction, and the effective andfunctional refractory periods of the atrium and the atrioventricular node.
No significant effects were observed on the His Purkinje system or the effective refractory periods of the ventricle.
In these actions atenolol closely resembles propranolol. However, because in contrast to propranolol it increases atrial refractoriness, it may have advantages in the treatment of atrial arrhythmias.
Beta-adrenergic blocking agents are widely used in the treatment of arrhythmias, particularly those of supraventricular origin.
Practolol was introduced as a cardioselective betablocking agent with the advantage over propranolol that it was less prone to causing bronchoconstriction or cardiac depression (Gibson, 1971; McNeill, 1971) . Practolol differs from propranolol electrophysiologically in that it produces less pronounced depression of atrioventricular conduction, possibly because of its intrinsic sympathomimetic action (Smithen et al., 1971) . It has recently been withdrawn from general use because of serious side effects (Felix et al., 1974; Wright, 1975) .
Atenolol is a new beta-adrenergic blocking agent which appears to possess a degree of cardioselectivity, equivalent to that of practolol (Vilsvik and Schaaning, 1976) . Its structural formula is illustrated in Fig. 1 . However, it lacks intrinsic sympathomimetic properties and unlike propranolol has no membrane stabilising action (Barrett et al., 1973) .
The aim of the present investigation was to evaluate the effects of atenolol on the specialised conduction system of the heart, particular attention being paid to conduction times and refractoriness at all levels of the conduction system. ' (1) sinus node function; (2) atrioventricular node conduction time; and (3) refractoriness at each level of the specialised conduction system and also of atrial and ventricular muscle using the extrastimulus technique (Goldreyer and Bigger, 1969) .
The atrium was paced at a constant rate higher than the spontaneous sinus rate and a premature extrastimulus was introduced after every eighth beat followed by an appropriate delay to avoid repetitive firing. By increasing the prematurity of the extrastimulus the refractory periods of the different cardiac tissues could be determined. Impulses of 2 milliseconds duration at twice diastolic threshold were used.
After control measurements had been taken the effects of intravenous atenolol were studied. The first part of the study was carried out to investigate the response to three graded doses of atenolol, 0 03, 0'06, and 0 12 mg/kg body weight on the specialised conducting system in 6 patients. In the second part of the study the electrophysiological effects of atenolol on the sinus node, atrium, specialised conducting system, and the ventricle were recorded at the highest dose level, 012 mg/kg body weight.
Definition of terms
Sinus node recovery time in the interval between the last paced beat and the first spontaneous sinus beat after two minutes of overdrive suppression of the sinus node at a rate faster than the sinus rate.
A is the right atrial electrogram. H is the His bundle potential recorded with bipolar electrodes 1 cm apart.
V is the earliest recorded ventricular activity taken from the surface leads or the intracardiac electrogram.
S refers to the pacing stimulus. QTc is the QT interval corrected to a cycle length of 10OOms
QTc= QTV/R-R This is taken as a measure of duration of ventricular repolarisation.
The AH interval as measured in the His bundle The effective refractory period (ERP) of the atrium is defined as the longest S1-S2 interval at which S2 fails to depolarise the atrium.
The functional refractory period (FRP) of the atrium is defined as the shortest A1-A2 interval recorded.
The effective refractory period of the atrioventricular node is defined as the longest A1-A2 interval at which A2 fails tb propagate to the His Purkinje system.
The functional refractory period of the atrioventricular node is defined as the shortest H1-H2 interval recorded.
The effective refractory period of the His Purkinje system is defined as the longest H1-H2 interval at which H2 fails to conduct to the ventricles.
The relative refractory period of the His Purkinje system is defined as the longest H1-H2 interval at which H2 is conducted to the ventricles with a longer HV time than that of the basic driving beat, or with a QRS complex of aberrant configuration.
The effective refractory period of the ventricle is defined as the longest S1-S2 interval at which S2 fails to depolarise the ventricle. 1  850  1080  1065  1110  100  110  30  40  400  365  2  1020  1125   --105  115  35  40  390  390  3  860  1048  980  1200  140  140  35  40  400  366  4  690  790  1065  1110  85  100  50  50  430  380  5  623  886  720  970  120  180  55  60  426  375  6  883  990  1110  1130  95  105  50  50  372  348  7  1050  1067  1380  1470  150  150   40  40  445  438  8  802  871  1090  1370  75  100  70  73  404  375  9  753  833  560  830  108  125  40  40  460 Tables 1 and 2. prolongation. There was a trend towards greater Mean values shown in these tables were calculated AH prolongation at each higher dose level of from patients with paired data only. atenolol (Fig. 2) . The difference at each paced cycle length was statistically significant between the Sinus node function (Table 1) lowest (003 mg/kg) and the highest (012 mg/kg) Sinus cycle length was increased in all 16 atenolol dose levels (P < 0 05). There was no signi-patients in whom it was measured, with an overall mean increase of 146 ±21 ms (P < 0.001), equivalent to a decrease in mean heart rate from 79±3 to 66 ±2 beats/minute. The sinus node recovery time was increased in all 9 patients in whom it was measured with a mean rise of 168 ±38 ms (P <0.01) and an example is shown in Fig. 3 . Atrioventricular nodal conduction (Table 1) During spontaneous sinus rhythm AH was increased in 14 out of 16 patients after atenolol and unchanged in 2 patients with an overall mean increase of 14 ±4 ms (P < 0-001). During atrial pacing at cycle lengths ranging from 360 to 790 ms atenolol consistently caused AH prolongation. Atenolol produced no significant change in HV during sinus rhythm or during atrial pacing.
Q-Tc (Table 1) was shortened in 9 out of 10 patients in whom it was measured and unchanged in 1 patient, with an overall mean decrease of 30±5 ms (P<0.001).
Atrial refractoriness (Table 2) The effective refractory period of the atrium was increased by atenolol in all 10 patients in whom it was measured at paced cycle lengths ranging from 360 to 730 ms. The mean increase was 31 ±6 ms (P < 0.001). An example is shown in Fig. 4 . There was a similar increase in the functional refractory period of the atrium with a mean change of 34 ±6 ms (P < 0-001).
Atrioventricular nodal refractory periods (Table 2) The effective refractory period of the atrioventricular node was increased by atenolol in 6 of the 7 patients in whom it could be measured at paced cycle lengths ranging from 430 to 770 ms. An example is shown in Fig. 5 . There was an overall mean increase of 51±17 ms (P<0.02).
The functional refractory period of the atrioventricular node was increased in 10 out of 10 patients with a mean increase of 42 ±12 ms (P < 0.01).
His Purkinje refractoriness (Table 2) The effective refractory period of the His Purkinje system could not be measured in any of the patients studied, because the functional refractory periods of either the atrioventricular node or the atrium were longer at the paced cycle lengths used, ranging from 360 to 790 ms.
The relative refractory period of the His Purkinje system could be measured in 6 out of 10 patients and showed no consistent change after administration of atenolol. group.bmj.com on January 7, 2018 -Published by http://heart.bmj.com/ Downloaded from Effective refractory period of the ventricle Atenolol produced no significant change in the effective refractory period of the right ventricle in the 6 patients in whom it was studied.
Arrhythmias
(1) Supraventricular One patient had a short run of supraventricular tachycardia induced during atrial pacing at a cycle length of 660 ms by a premature extrastimulus at an S1-S2 interval of 205 ms. After atenolol 0 12 mg/kg premature extrastimuli, including ones presented at the same coupling interval, failed to produce tachycardia. (2) Ventricular Two patients had frequent ventricular extrasystoles which were abolished by atenolol and one of these patients had in addition spontaneous self-limiting episodes of ventricular tachycardia which were abolished by the drug.
Discussion
Atenolol causes significant prolongation of the sinus cycle length, sinus node recovery time, atrioventricular node conduction, and the effective and functional refractory periods of the atrium and atrioventricular node. No significant effect was observed on the His Purkinje system or the effective refractory period of the ventricle.
In these actions atenolol clearly resembles propranolol (Seides et al., 1974) which also prolongs sinus cycle length, atrioventricular node conduction, and the refractory periods of the atrioventricular node. Propranolol, however, has not been shown to cause significant prolongation of atrial refractoriness. Theoretically, this difference should give atenolol an advantage over propranolol in the treatment of arrhythmias involving the atrium.
Atenolol differs from practolol in its prolongation of atrioventricular node conduction (Smithen et al., 1971) . Presumably this is because like propranolol it lacks intrinsic sympathomimetic properties. Atenolol has been shown to be as cardioselective as practolol on the bronchial tree (Vilsvik and Schaaning, 1976) but not on the peripheral circulatory system (Robinson et al., 1978) . It, therefore, resembles propranolol haemodynamically as well as electrophysiologically.
Like other beta-blocking agents which are classified as possessing Class 2 actions by Vaughan , atenolol differs from drugs with mainly Class I actions. Thus it differs from quinidine (Josephson et al., 1974b) and procainamide (Josephson et al., 1974a) which prolong His Purkinje conduction and refractoriness and decrease the effective refractory period of the atrioventricular node. The actions of these two agents are classified as subgroup la. Atenolol also differs from mexiletine (McComish et al., 1975) , lignocaine (Josephson et al., 1972) , and diphenylhydantoin (Caracta et al., 1973) which all shorten the refractory period of the His Purkinje system and their actions are classified as subgroup lb. Atenolol does not prolong action potential duration experimentally (Barrett et al., 1973) as does amiodarone (Singh and Vaughan Williams, 1970) , i.e. it possesses no class III actions.
Although atenolol has not been shown to affect the His Purkinje system in our patients with normal conducting systems, it should not be assumed that it is, therefore, safe to use in patients with conducting system disease.
In conclusion, atenolol is a new cardioselective beta-adrenergic blocking agent which, like other beta-blockers, would be a suitable agent in the treatment of supraventricular arrhythmias in particular. Though relatively selective on the bronchial tree its action electrophysiologically differs from practolol. Electrophysiologically it closely resembles propranolol and because of its action in increasing atrial refractoriness may prove to be more effective than propranolol in the treatment of supraventricular arrhythmias. 
